Dissociating HDL cholesterol from cardiovascular risk.
Hausenloy
Derek J
DJ
The Hatter Cardiovascular Institute, University College London Hospital, London WC1E 6HX, UK. d.hausenloy@ucl.ac.uk
Opie
Lionel
L
Yellon
Derek M
DM
D000577:Amides; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects*; D004952:Esters; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D023303:Oxazolidinones / Q000494:pharmacology; D011237:Predictive Value of Tests; D011322:Primary Prevention / Q000379:methods; D011804:Quinolines / Q000494:pharmacology; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods; D013438:Sulfhydryl Compounds / Q000494:pharmacology
D000577:Amides; D000924:Anticholesteremic Agents; D015415:Biomarkers; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D004952:Esters; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D023303:Oxazolidinones; D011804:Quinolines; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; C483909:torcetrapib; C530884:anacetrapib